Low and Declining Rate of 4-Class ARV Resistance Among Treatment-Experienced Patients in the EuResist Database

Source: 2020 Conference on Retroviruses and Opportunistic Infections*
Download Slideset
March 8-11, 2020; Boston, Massachusetts
Analysis of the EuResist database reveals prevalence and predictors of resistance to all 4 main ARV drug classes in treatment-experienced patients in Europe.
Format: Microsoft PowerPoint (.ppt)
File Size: 158 KB
Released: March 15, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

Clinical Care Options (CCO) expert analysis of new data from AIDS 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: September 20, 2022

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Released: September 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings